The Food and Drug Administration granted Keryx Biopharmaceuticals Inc.'s (Nasdaq: KERX) refractory advanced colorectal cancer treatment KRX-0401 Fast Track status sending the stock price soaring 69 cents to $3.43.
Keryx Granted Fast Track Status
April 05, 2010 at 11:20 AM EDT
